

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/596,010	03/13/2007	Erik Andreasson	09663.0068USWO	1703	
23552 7590 09/04/2008 MERCHANT & GOULD PC			EXAMINER		
P.O. BOX 2903 MINNEAPOLIS, MN 55402-0903			IBRAHIM, MEDINA AHMED		
			ART UNIT	PAPER NUMBER	
			1638		
			MAIL DATE	DELIVERY MODE	
			09/04/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/596,010 ANDREASSON ET AL. Office Action Summary Examiner Art Unit

		Medina A. Ibrahim	1638	
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	correspondence ad	dress
A SHOWHIC - External after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY THEVER IS LONGER, FROM THE MAILING DY Stones of time may be available under the provisions of 3° CFR. 13° SIX (6) MORTHS from the mailing date of this communication. SIX (6) MORTHS from the mailing date of this communication print of very by specified above, the maximum salutably paried we pupit for righty is specified above, the maximum salutably paried we uply received by the Office later than three months after the mailing departed term daylearners. Sea 3° CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tin till apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this o D (35 U.S.C. § 133).	,
Status				
2a)□	Responsive to communication(s) filed on <u>13 M</u> . This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under <u>E</u>	action is non-final. ace except for formal matters, pro		e merits is
Dispositi	on of Claims			
5) 6) 7)	Claim(s) 27-48 is/are pending in the application (as) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are allowed. Claim(s) is/are objected to. Claim(s) 27-48 are subject to restriction and/or	vn from consideration.		
Applicati	on Papers			
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the c Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	epted or b) objected to by the I drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 C	
Priority ι	ınder 35 U.S.C. § 119			
a)[Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 3. Copies of the certified copies of the priori priority documents as the copies of the priority documents are copies of the certified copies of the priority documents are copies of the certified copies of the priority documents are copies of the certified copies of the priority documents are copies of the certified copies of the priority documents are copies of the certified copies of the priority documents are copies of the certified copies of the certified copies of the priority documents are copies of the certified copies of the priority documents are copies of the priority documents.	s have been received. s have been received in Applicati ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National	Stage
Attachmen	t(s)			
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da		

Attachment(s)		
1) Notice of References Cited (PTO-892) Notice of Draftsperson's Patient Drawing Review (PTO-948) Notice of Draftsperson's Patient Drawing Review (PTO-948) Notice of Draftsperson's Patient Notice (PTO/SE/CB) Paper No(s)Mail Date Paper No(s)	Interview Summary (PTO-413) Paper No(s)Mail Date. Notice of Informal Patent Arglication Other:	

Application/Control Number: 10/596,010 Page 2

Art Unit: 1638

DETAILED ACTION

In a preliminary examination, it is noted that claim 27 recites sequences with no sequence identifiers (SEQ ID NO:). Applicant, therefore, is required to identify the sequences of parts (a) and (b) of claim 27 by SEQ ID NO:, or to submit new sequence listings comprising said sequences.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 27-43, drawn to a disease resistant transgenic plant, seed thereof, and a plant transformation method.

Group II, claim(s) 44-48, drawn to a method of selecting a plant using antibody, and antibody reactive to a specific polypeptide sequence.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Inventions I and II are not so linked by a single special technical feature because they are drawn to different methods using functionally and structurally different products having different effects and uses. The special technical feature of Group I that is not recited in Group II is the plant transformation method. The special technical feature of Group II that is not recited in Group I is the antibody and selection of plants using said

Application/Control Number: 10/596,010

Art Unit: 1638

antibody.

For each of the inventions I and II, Applicant is also required to elect one sequence. For the invention of Group I, Applicant is required to elect one DNA sequence or a DNA sequence encoding one of the polypeptides of SEQ ID NO: 2, 6, 10, 14, 16, 20, 26, 27 or 28. For the invention of Group II, Applicant is required to elect one isolated polypeptide sequence from claim 28.

The nucleotide sequences of the claims (or the encoded proteins), are not so linked by a single special technical feature because there is no shared significant structural element between the nucleotide sequences listed in claim 1(or the encoded proteins). Therefore, the nucleotide/protein sequences of the claims are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Therefore, for all the reasons discussed above, invention I-II lack unity.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Art Unit: 1638

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Medina A. Ibrahim whose telephone number is (571)272-0797. The examiner can normally be reached on M-TH 8:00 am to 5:30 PM, and every other Friday from 8:00 AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on 571-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/596,010 Page 5

Art Unit: 1638

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MAI 9/2/2008 /Medina A Ibrahim/ Primary Examiner, Art Unit 1638 Application Number

 Application/Control No.
 Applicant(s)/Patent under Reexamination

 10/596,010
 ANDREASSON ET AL.

 Examiner
 Art Unit

 Medina A. Ibrahim
 1638